ARGN – Acumen Pharmaceuticals Inc

Latest News & Stock Analysis

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid-beta oligomers (AβOs) for the treatment of Alzheimer’s disease. Acumen’s innovative approach aims to halt the progression of Alzheimer’s by addressing what they believe is a root cause of the disease. The lead candidate, ACU193, is a monoclonal antibody that selectively binds to AβOs, offering a differentiated mechanism of action in the fight against Alzheimer’s. Investors interested in stocks, investment, news on ARGN, and analysis of ARGN should follow Acumen’s progress in the biotechnology and pharmaceutical market.

Argan: Engineering Growth in Construction and Energy?
ARGN

Argan: Engineering Growth in Construction and Energy?

by | 07/11/2024 05:54 AM | ARGN

🏗️ Argan operates in key areas like energy industry services and telecommunications infrastructure.

🚀 The company is well-positioned to capitalize on the resurgence of industries in the U.S.

📈 It shows impressive growth, with a significant project backlog.

💰 Expected growth in earnings per share (EPS) and revenues makes it a solid industrial sector pick.

Read more!